Dioxane-Linked Amide Derivatives as Novel Bacterial Topoisomerase Inhibitors against Gram-Positive Staphylococcus aureus.

In recent years, novel bacterial topoisomerase inhibitors (NBTIs) have been developed as future antibacterials for treating multidrug-resistant bacterial infections. A series of dioxane-linked NBTIs with an amide moiety has been synthesized and evaluated. Compound 3 inhibits DNA gyrase, induces the formation of single strand breaks to bacterial DNA, and achieves potent antibacterial activity against a variety of Gram-positive pathogens, including methicillin-resistant Staphylococcus aureus (MRSA). Optimization of this series of analogues led to the discovery of a subseries of compounds (22-25) with more potent anti-MRSA activity, dual inhibition of DNA gyrase and topoisomerase IV, and the ability to induce double strand breaks through inhibition of S. aureus DNA gyrase.

[1]  Mark J. Mitton-Fry,et al.  Novel bacterial topoisomerase inhibitors derived from isomannide. , 2020, European journal of medicinal chemistry.

[2]  D. Landman,et al.  Emergence of Delafloxacin-Resistant Staphylococcus aureus in Brooklyn, NY. , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[3]  Prabasaj Paul,et al.  Multidrug-Resistant Bacterial Infections in U.S. Hospitalized Patients, 2012-2017. , 2020, The New England journal of medicine.

[4]  R. Alm,et al.  Innovation in AMR - the CARB-X Perspective. , 2020, ACS infectious diseases.

[5]  M. Anderluh,et al.  Two Decades of Successful SAR-Grounded Stories of the Novel Bacterial Topoisomerase Inhibitors (NBTIs) , 2020, Journal of medicinal chemistry.

[6]  N. Osheroff,et al.  Bimodal actions of a naphthyridone/aminopiperidine-based antibacterial that targets gyrase and topoisomerase IV. , 2019, Biochemistry.

[7]  G. Murshudov,et al.  DNA Topoisomerase Inhibitors: Trapping a DNA-Cleaving Machine in Motion , 2019, Journal of molecular biology.

[8]  G. Mangano,et al.  The crystal structure of S. aureus Gyrase complex with ID-130 and DNA , 2019 .

[9]  Mark J. Mitton-Fry,et al.  1,3-Dioxane-Linked Bacterial Topoisomerase Inhibitors with Enhanced Antibacterial Activity and Reduced hERG Inhibition. , 2019, ACS infectious diseases.

[10]  N. Osheroff,et al.  Mechanistic and Structural Basis for the Actions of the Antibacterial Gepotidacin against Staphylococcus aureus Gyrase. , 2019, ACS infectious diseases.

[11]  N. Minovski,et al.  Novel bacterial topoisomerase inhibitors: challenges and perspectives in reducing hERG toxicity. , 2018, Future medicinal chemistry.

[12]  Mark J. Mitton-Fry,et al.  Synthesis and anti-staphylococcal activity of novel bacterial topoisomerase inhibitors with a 5-amino-1,3-dioxane linker moiety. , 2018, Bioorganic & medicinal chemistry letters.

[13]  G. Stein,et al.  Delafloxacin: A New Anti-methicillin-resistant Staphylococcus aureus Fluoroquinolone. , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  N. Osheroff,et al.  Mechanism of Action of Mycobacterium tuberculosis Gyrase Inhibitors: A Novel Class of Gyrase Poisons. , 2018, ACS infectious diseases.

[15]  M. De Vivo,et al.  Novel Bacterial Topoisomerase Inhibitors Exploit Asp83 and the Intrinsic Flexibility of the DNA Gyrase Binding Site , 2018, International journal of molecular sciences.

[16]  M. Ouellette,et al.  Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. , 2017, The Lancet. Infectious diseases.

[17]  Mark J. Mitton-Fry,et al.  Novel Bacterial Type II Topoisomerase Inhibitors , 2017 .

[18]  Mark J. Mitton-Fry,et al.  Novel 3-fluoro-6-methoxyquinoline derivatives as inhibitors of bacterial DNA gyrase and topoisomerase IV. , 2017, Bioorganic & medicinal chemistry letters.

[19]  M. Hackel,et al.  In Vitro Activity of Gepotidacin, a Novel Triazaacenaphthylene Bacterial Topoisomerase Inhibitor, against a Broad Spectrum of Bacterial Pathogens , 2016, Antimicrobial Agents and Chemotherapy.

[20]  Akinori Nishimura,et al.  Structure activity relationship of pyridoxazinone substituted RHS analogs of oxabicyclooctane-linked 1,5-naphthyridinyl novel bacterial topoisomerase inhibitors as broad-spectrum antibacterial agents (Part-6). , 2015, Bioorganic & medicinal chemistry letters.

[21]  R. Alm,et al.  Insights into the Mechanism of Inhibition of Novel Bacterial Topoisomerase Inhibitors from Characterization of Resistant Mutants of Staphylococcus aureus , 2015, Antimicrobial Agents and Chemotherapy.

[22]  R. Nargund,et al.  Hydroxy tricyclic 1,5-naphthyridinone oxabicyclooctane-linked novel bacterial topoisomerase inhibitors as broad-spectrum antibacterial agents-SAR of RHS moiety (Part-3). , 2015, Bioorganic & medicinal chemistry letters.

[23]  D. Ritz,et al.  Novel tetrahydropyran-based bacterial topoisomerase inhibitors with potent anti-gram positive activity and improved safety profile. , 2015, Journal of medicinal chemistry.

[24]  T. Dougherty,et al.  Optimization of physicochemical properties and safety profile of novel bacterial topoisomerase type II inhibitors (NBTIs) with activity against Pseudomonas aeruginosa. , 2014, Bioorganic & medicinal chemistry.

[25]  S. Solomon,et al.  Antibiotic resistance threats in the United States: stepping back from the brink. , 2014, American family physician.

[26]  Anirban Ghosh,et al.  Novel N-linked aminopiperidine-based gyrase inhibitors with improved hERG and in vivo efficacy against Mycobacterium tuberculosis. , 2014, Journal of medicinal chemistry.

[27]  C. Mayer,et al.  Non-quinolone inhibitors of bacterial type IIA topoisomerases: a feat of bioisosterism. , 2014, Chemical reviews.

[28]  J. Hermes,et al.  Discovery of MK-7655, a β-lactamase inhibitor for combination with Primaxin®. , 2014, Bioorganic & medicinal chemistry letters.

[29]  Wolfgang Keck,et al.  Design, synthesis, and characterization of novel tetrahydropyran-based bacterial topoisomerase inhibitors with potent anti-gram-positive activity. , 2013, Journal of medicinal chemistry.

[30]  Mark J. Mitton-Fry,et al.  Novel quinoline derivatives as inhibitors of bacterial DNA gyrase and topoisomerase IV. , 2013, Bioorganic & medicinal chemistry letters.

[31]  A. Shapiro,et al.  Allosteric inhibition of the DNA-dependent ATPase activity of Escherichia coli DNA gyrase by a representative of a novel class of inhibitors. , 2012, Biochemical pharmacology.

[32]  D. Ehmann,et al.  Novel N-linked aminopiperidine inhibitors of bacterial topoisomerase type II with reduced pK(a): antibacterial agents with an improved safety profile. , 2012, Journal of medicinal chemistry.

[33]  Kristin K. Brown,et al.  Type IIA topoisomerase inhibition by a new class of antibacterial agents , 2010, Nature.

[34]  E. Honig,et al.  Emergence of community-acquired meticillin-resistant Staphylococcus aureus strain USA300 as a cause of necrotising community-onset pneumonia. , 2009, The Lancet. Infectious diseases.

[35]  D. Platel,et al.  Mechanism of Action of the Antibiotic NXL101, a Novel Nonfluoroquinolone Inhibitor of Bacterial Type II Topoisomerases , 2008, Antimicrobial Agents and Chemotherapy.

[36]  John J. M. Wiener,et al.  Tetrahydroindazole inhibitors of bacterial type II topoisomerases. Part 2: SAR development and potency against multidrug-resistant strains. , 2007, Bioorganic & medicinal chemistry letters.

[37]  John J. M. Wiener,et al.  Novel pyrazole derivatives as potent inhibitors of type II topoisomerases. Part 1: synthesis and preliminary SAR analysis. , 2007, Bioorganic & medicinal chemistry letters.

[38]  Matthew P. Repasky,et al.  Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. , 2004, Journal of medicinal chemistry.

[39]  Clifton E. Barry,et al.  A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis , 2000, Nature.

[40]  A. Khodursky,et al.  The Mechanism of Inhibition of Topoisomerase IV by Quinolone Antibacterials* , 1998, The Journal of Biological Chemistry.

[41]  J. Waitz.  Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically , 1990 .

[42]  Eric Pérez Salvà,et al.  Determination of the , 1981 .